Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Human Polyclonal APOA4 Primary Antibody for IHC, IHC (p) - ABIN4281185
Levin, Wang, Schwarz, Koethe, Leweke, Bahn: Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. in Molecular psychiatry 2010
Show all 2 Pubmed References
Human Monoclonal APOA4 Primary Antibody for ELISA, WB - ABIN968958
Peignon, Thenet, Schreider, Fouquet, Ribeiro, Dussaulx, Chambaz, Cardot, Pinçon-Raymond, Le Beyec: E-cadherin-dependent transcriptional control of apolipoprotein A-IV gene expression in intestinal epithelial cells: a role for the hepatic nuclear factor 4. in The Journal of biological chemistry 2006
Show all 2 Pubmed References
Human Monoclonal APOA4 Primary Antibody for ELISA, WB - ABIN968959
Chien, Chen, Hsu, Su, Chang, Lee, Lee: Genetic association study of APOA1/C3/A4/A5 gene cluster and haplotypes on triglyceride and HDL cholesterol in a community-based population. in Clinica chimica acta; international journal of clinical chemistry 2007
Show all 2 Pubmed References
Human Polyclonal APOA4 Primary Antibody for WB - ABIN2785651
Penco, Buscema, Patrosso, Marocchi, Grossi: New application of intelligent agents in sporadic amyotrophic lateral sclerosis identifies unexpected specific genetic background. in BMC bioinformatics 2008
Human Polyclonal APOA4 Primary Antibody for IHC, IHC (p) - ABIN4281184
Kato, Nicholson, Neiman, Rantalainen, Holmes, Barrett, Uhlén, Nilsson, Spector, Schwenk: Variance decomposition of protein profiles from antibody arrays using a longitudinal twin model. in Proteome science 2011
Mouse (Murine) Polyclonal APOA4 Primary Antibody for ELISA, IHC - ABIN449527
Orsó, Moehle, Boettcher, Szakszon, Werner, Langmann, Liebisch, Buechler, Ritter, Kronenberg, Dieplinger, Bornstein, Stremmel, Schmitz: The satiety factor apolipoprotein A-IV modulates intestinal epithelial permeability through its interaction with alpha-catenin: implications for inflammatory bowel diseases. in Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2007
Human Polyclonal APOA4 Primary Antibody for IHC (p), IHC - ABIN188729
Spaulding, Saijo, Turnage, Alexander, Aw, Kalogeris: Apolipoprotein A-IV attenuates oxidant-induced apoptosis in mitotic competent, undifferentiated cells by modulating intracellular glutathione redox balance. in American journal of physiology. Cell physiology 2005
Human Polyclonal APOA4 Primary Antibody for IHC (p), WB - ABIN513413
Huang, Wu, Tseng, Chen, Hsieh, Chen: Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease. in PLoS ONE 2011
The genotype-risk associations were examined between APOA4 (rs5095, rs675, rs5110) and obesity-related phenotypes and other comorbidities in Sucre, Venezuela. There was a higher average waist-hip ratio among rs5095 homozygotes and for conicity index among homozygotes for rs5110.
Apolipoprotein L1 (show APOL1 Antibodies) and apolipoprotein A-IV and their association with kidney function
APOA-IV glycation is associated with coronary artery disease severity in patients with Type 2 Diabetes Mellitus.
These findings indicate that LZIP (show CREB3 Antibodies) is a novel modulator of APOA4 expression and hepatic lipid metabolism.
Study discovered novel and independent associations of prediabetes and related traits with MASP1 (show MASP1 Antibodies), and some evidence for associations with THBS1 (show THBS1 Antibodies), GPLD1 (show GPLD1 Antibodies) and ApoA-IV, suggesting a role for these proteins in the pathophysiology of type 2 diabetes.
Analyses of SNP-scores indicate potential causal effects of kidney function and by lesser extent triglycerides on apoA-IV concentrations.
Low levels of APOA1 (show APOA1 Antibodies), APOC3 (show APOC3 Antibodies), and APOA4 are associated with risk of Alzheimer disease.
Single nucleotide polymorphisms (Rs7396835) of APOA4 protein did not increase the risk of CHD (show CHDH Antibodies) in the Chinese population.
ApoA-IV colocalizes with NR4A1 (show NR4A1 Antibodies), which suppresses G6Pase (show G6PC Antibodies) and PEPCK (show PEPCK Antibodies) gene expression at the transcriptional level, reducing hepatic glucose output and lowering blood glucose.
the present findings reveal that High-altitude polycythemia -induced gastric mucosal lesion inspires the protection responses by up-regulating APOA4 and APOC3 (show APOC3 Antibodies), and down-regulating GIF (show GIF Antibodies).
MTTP (show MTTP Antibodies) is regulated by apo A-IV in manner to promote increased packaging of triglyceride into chylomicron core, which may be important in neonatal fat absorption.
down-regulation of apolipoprotein A-I (show APOA1 Antibodies) and A-IV messages in the liver may be mediated by interleukin 6 (show IL6 Antibodies) and tumor necrosis factor-alpha (show TNF Antibodies)
Hepatocyte nuclear factor 4 alpha (HNF-4 alpha (show HNF4A Antibodies))induces apoliprotein IV gene in response to dietary lipids in the intestine.
APOA4 genes with SNPs
Upregulation of the intestinal apolipoprotein APOA-IV in horses with chronic laminitis was confirmed by western blot.[APOA-IV]
This study uncovers an anti-sense lncRNA (APOA4-AS), which is co-expressed with APOA4, and concordantly and specifically regulates APOA4 expression both in vitro and in vivo with the involvement of HuR (show ELAVL1 Antibodies).
Our findings may throw light on the function of ApoA4 in inflammatory responses and acute-phase reactions, as well as the development of SERPINA3 (show SERPINA3 Antibodies) relative diseases.
Very Low Density Lipoprotein (VLDL) assembly and CREBH (show CREB3L3 Antibodies) activation play key roles in the response to hepatic steatosis by up-regulating apoA-IV and promoting assembly and secretion of larger, more triglyceride - enriched VLDL particles.
It was suggested that increased ileal GPR119 (show GPR119 Antibodies) is a potential mechanism by which GLP-1 (show GCG Antibodies) secretion is enhanced in apoA-IV-/- mice.
these data suggest that apoA-IV is not necessary for the metabolic improvements shown with VSG, but also suggest an interesting role for apoA-IV in regulating macronutrient preference and hepatic triglyceride levels.
These results reveal ApoA-IV as a novel follicle-associated epithelium-specific marker especially in the upper small intestine of adult mice.
transcriptional regulation of apolipoprotein A-IV by the transcription factor CREBH (show CREB3L3 Antibodies)
apoA-IV inhibits hepatic gluconeogenesis by decreasing Glc-6-Pase (show G6PC Antibodies) and PEPCK (show PEPCK Antibodies) gene expression through NR1D1 (show NR1D1 Antibodies).
Hepatic steatosis in mice induces hepatic apoA-IV expression, which in turn promotes lipoprotein particle expansion and reduces hepatic lipid burden without increasing the number of secreted atherogenic apoB (show APOB Antibodies)-containing lipoprotein particles.
Data indicate that plasma lipids, lipid absorption, and microsomal triglyceride transfer protein (MTP (show MTTP Antibodies)), FoxO1 (show FOXO1 Antibodies), and FoxA2 (show FOXA2 Antibodies) levels are lower at night and at mealtime in apoAIV-/- mice.
Apoliprotein (apo) A-IV gene contains 3 exons separated by two introns. A sequence polymorphism has been identified in the 3'UTR of the third exon. The primary translation product is a 396-residue preprotein which after proteolytic processing is secreted its primary site of synthesis, the intestine, in association with chylomicron particles. Although its precise function is not known, apo A-IV is a potent activator of lecithin-cholesterol acyltransferase in vitro.
, apolipoprotein A4
, apolipoprotein A-IV
, apolipoprotein A-IV-like